ArticleMicrobial cell factories2014
Production of shikimic acid from Escherichia coli through chemically inducible chromosomal evolution and cofactor metabolic engineering.
Article in Microbial cell factories, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 105 citations in OpenAlex.
- Comparative analysis of precursor supply and pathway reinforcement strategies for shikimic acid biosynthesis in Pseudomonas putida.Microbial cell factories · 2026Article
- Anaerobic metabolic evolution for homotypic L-valine fermentation.Nature communications · 2026Article
- Co-Immobilization of SpyTag-Cyclized Enzymes on a γPFD-SpyCatcher Hydrogel to Address Broad Specificity.Gels (Basel, Switzerland) · 2026Article
- Advances in metabolic engineering of Bacillus subtilis towards high-efficiency cytidine biosynthesis.World journal of microbiology & biotechnology · 2026Review
- Advances in microbial mevalonolactone production: from fermentative mevalonate accumulation to downstream lactonization.Engineering microbiology · 2026Review
- Optimizing L-Tryptophan Production inJournal of microbiology and biotechnology · 2025Article
- Metabolic engineeringSynthetic and systems biotechnology · 2025Article
- Microbial engineering for monocyclic aromatic compounds production.FEMS microbiology reviews · 2025Review
- Cofactor engineering for improved production of 2,4-dihydroxybutyric acid via the synthetic homoserine pathway.Frontiers in bioengineering and biotechnology · 2025Article
- Production of succinate with two COMicrobial cell factories · 2024Article
- Multiple Metabolic Engineering Strategies to Improve Shikimate Titer inMetabolites · 2023Article
- Metabolic Engineering of Shikimic Acid Biosynthesis Pathway for the Production of Shikimic Acid and Its Branched Products in Microorganisms: Advances and Prospects.Molecules (Basel, Switzerland) · 2022Review
- inPOSE: A Flexible Toolbox for Chromosomal Cloning and Amplification of Bacterial Transgenes.Microorganisms · 2022Article
- Advances and prospects in metabolic engineering of Escherichia coli for L-tryptophan production.World journal of microbiology & biotechnology · 2022Review
- Exploitation of Hetero- and Phototrophic Metabolic Modules for Redox-Intensive Whole-Cell Biocatalysis.Frontiers in bioengineering and biotechnology · 2022Review
- Ferulic acid production by metabolically engineered Escherichia coli.Bioresources and bioprocessing · 2021Article
- EngineeringSynthetic and systems biotechnology · 2020Article
- Metabolic engineering of Escherichia coli for production of chemicals derived from the shikimate pathway.Journal of industrial microbiology & biotechnology · 2020Review
- Recent Advances in Metabolically Engineered Microorganisms for the Production of Aromatic Chemicals Derived From Aromatic Amino Acids.Frontiers in bioengineering and biotechnology · 2020Review
- Bioprocess Optimization for the Production of Aromatic Compounds With Metabolically Engineered Hosts: Recent Developments and Future Challenges.Frontiers in bioengineering and biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundShikimic acid (SA) produced from the seeds of Chinese star anise (Illicium verum) is a key intermediate for the synthesis of neuraminidase inhibitors such as oseltamivir (Tamiflu®), an anti-influenza drug. However, plants cannot deliver a stable supply of SA. To avoid the resulting shortages and price fluctuations, a stable source of affordable SA is required. Although recent achievements in metabolic engineering of Escherichia coli strains have significantly increased SA productivity, commonly-used plasmid-based expression systems are prone to genetic instability and require constant selective pressure to ensure plasmid maintenance. Cofactors also play an important role in the biosynthesis of different fermentation products. In this study, we first constructed an E. coli SA production strain that carries no plasmid or antibiotic marker. We then investigated the effect of endogenous NADPH availability on SA production.
resultsThe pps and csrB genes were first overexpressed by replacing their native promoter and integrating an additional copy of the genes in a double gene knockout (aroK and aroL) of E. coli. The aroG(fbr), aroB, aroE and tktA gene cluster was integrated into the above E. coli chromosome by direct transformation. The gene copy number was then evolved to the desired value by triclosan induction. The resulting strain, E. coli SA110, produced 8.9-fold more SA than did the parental strain E. coli (ΔaroKΔaroL). Following qRT-PCR analysis, another copy of the tktA gene under the control of the 5P(tac) promoter was inserted into the chromosome of E. coli SA110 to obtain the more productive strain E. coli SA110. Next, the NADPH availability was increased by overexpressing the pntAB or nadK genes, which further enhanced SA production. The final strain, E. coli SA116, produced 3.12 g/L of SA with a yield on glucose substrate of 0.33 mol/mol.
conclusionAn SA-producing E. coli strain that carries neither a plasmid nor an antibiotic marker was constructed by triclosan-induced chromosomal evolution. We present the first demonstration that increasing NADPH availability by overexpressing the pntAB or nadK genes significantly enhances SA production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.